These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 480619)

  • 21. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiological importance of vitamin D metabolism.
    Haussler MR; Chandler JS; Pike JW; Brumbaugh PF; Speer DP; Pitt MJ
    Prog Biochem Pharmacol; 1980; 17():134-42. PubMed ID: 6259650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium and parathyroid disorders in children. Chronic renal failure and treatment with calcitriol.
    Chan JC; DeLuca HR
    JAMA; 1979 Mar; 241(12):1242-4. PubMed ID: 762789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in vitamin D metabolism as they pertain to chronic renal disease.
    Coburn JW; Hartenbower DL; Brickman AS
    Am J Clin Nutr; 1976 Nov; 29(11):1283-99. PubMed ID: 187055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized double blind study of 1, 25(OH)2D3 in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC; Kleit SA
    Proc Clin Dial Transplant Forum; 1977; 7():166-9. PubMed ID: 210446
    [No Abstract]   [Full Text] [Related]  

  • 26. Zinc metabolism in patients with chronic renal failure during treatment with 1.25-dihydroxycholecalciferol: a controlled therapeutic trial.
    Kiilerich S; Christiansen C; Christensen MS; Naestoft J
    Clin Nephrol; 1981 Jan; 15(1):23-7. PubMed ID: 7214749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in renal slices from the rat.
    Armbrecht HJ; Zenser TV; Davis BB
    Endocrinology; 1981 Jul; 109(1):218-22. PubMed ID: 6972300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impairment of renal function in patients on 1alpha-hydroxycholecalciferol.
    Lancet; 1978 Aug; 2(8086):427-8. PubMed ID: 79789
    [No Abstract]   [Full Text] [Related]  

  • 29. Letter: Idiosyncratic reaction to 25-hydroxylated Vitamin D3.
    Gegick CG; Danowski TS; De Luca HF; Holick MF
    Ann Intern Med; 1974 Mar; 80(3):416-7. PubMed ID: 4816190
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effects of 1,24 R-dihydroxycholecalciferol on the calcium metabolism and renal function in predialysis chronic renal failure].
    Koshikawa S; Sekiguchi T; Akisawa T; Tamura K; Asano Y; Takeda K
    Nihon Jinzo Gakkai Shi; 1986 Apr; 28(4):429-37. PubMed ID: 3747254
    [No Abstract]   [Full Text] [Related]  

  • 31. Prolactin but not growth hormone stimulates 1,25-dihydroxyvitamin D3 production by chick renal preparations in vitro.
    Bikle DD; Spencer EM; Burke WH; Rost CR
    Endocrinology; 1980 Jul; 107(1):81-4. PubMed ID: 6892897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization.
    Costa T; Marie PJ; Scriver CR; Cole DE; Reade TM; Nogrady B; Glorieux FH; Delvin EE
    J Clin Endocrinol Metab; 1981 Mar; 52(3):463-72. PubMed ID: 6893992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcitriol in dialysis patients.
    Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC
    Clin Pharmacol Ther; 1978 May; 23(5):515-9. PubMed ID: 205382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
    Kanis JA; Cundy T; Earnshaw M; Henderson RG; Heynen G; Naik R; Russell RG; Smith R; Woods CG
    Q J Med; 1979 Apr; 48(190):289-322. PubMed ID: 504552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man.
    Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW
    J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of 1,25-dihydroxyvitamin D3 in early renal failure.
    Goodman WG; Coburn JW
    Annu Rev Med; 1992; 43():227-37. PubMed ID: 1580587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic 1,25-dihydroxyvitamin D3 administration in the rat reduces the serum concentration of 25-hydroxyvitamin D by increasing metabolic clearance rate.
    Halloran BP; Bikle DD; Levens MJ; Castro ME; Globus RK; Holton E
    J Clin Invest; 1986 Sep; 78(3):622-8. PubMed ID: 3489007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal effect of vitamin D metabolites: evidence for the essential role of the 25(OH) group.
    Friedlaender MM; Kornberg Z; Wald H; Popovtzer MM
    Am J Physiol; 1983 Jun; 244(6):F674-8. PubMed ID: 6602555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.
    Main J; Velasco N; Catto GR; Fraser RA; Edward N; Adami S; O'Riordan JL
    Clin Nephrol; 1986 Dec; 26(6):279-87. PubMed ID: 3542321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1,25(OH)2D3 is not the only D metabolite involved in the pathogenesis of osteomalacia.
    Rasmussen H; Baron R; Broadus A; DeFronzo R; Lang R; Horst R
    Am J Med; 1980 Sep; 69(3):360-8. PubMed ID: 6251721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.